Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept for neuroinflammation in mild cognitive impairment due to Alzheimer's disease
ISRCTN12472821Phase 2Completed
- Sponsor
- University of Southampton
- Start
- Sep 2015
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, double-blind trial in mild cognitive impairment due to Alzheimer's disease comparing Etanercept with Placebo (2 arms). Primary endpoint: Change in microglial activation on [11C] (R)-PK-111-95 PET. Started Sep 2015; status: completed.
02
Drugs
etanercept
03
Conditions
mild cognitive impairment due to Alzheimer's disease
Beyond the preview
Go deeper on ISRCTN12472821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN12472821.